Champions Oncology (CSBR) Share-based Compensation (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Share-based Compensation of $423000.0 in Q1 2026, up 69.88% quarter-over-quarter from $249000.0 in Q4 2025, and up 65.23% on a YoY basis from $256000.0 in Q1 2025.
Champions Oncology (CSBR) Share-based Compensation (2010 - 2026) Analysis & Trends
Champions Oncology's Share-based Compensation history runs 17 years deep, the most recent figure standing at $423000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 65.23% year-over-year to $423000.0; the TTM figure through Jan 2026 stood at $1.0 million (up 28.63% YoY), while the FY2025 annual figure was $654000.0, down 41.5% from the prior year.
- Share-based Compensation was $423000.0 for Q1 2026 at Champions Oncology, up from $249000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $423000.0 in Q3 2023 to a low of $9000.0 in Q4 2024.
- Historically, Share-based Compensation has averaged $236117.6 across 5 years, with a median of $249000.0 in 2025.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation tumbled 83.02% in 2024, then jumped 2666.67% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $119000.0 in 2022, then plunged by 55.46% to $53000.0 in 2023, then sank by 83.02% to $9000.0 in 2024, then surged by 2666.67% to $249000.0 in 2025, then surged by 69.88% to $423000.0 in 2026.
- The last three Share-based Compensation figures came in at $423000.0 (Q1 2026), $249000.0 (Q4 2025), and $208000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 26.47 Mn |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | 423,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 423,000.00 |
| Jan 31, 2026 | 423,000.00 |
| Oct 31, 2025 | 249,000.00 |
| Oct 31, 2025 | 249,000.00 |
| Jul 31, 2025 | 208,000.00 |
| Jul 31, 2025 | 208,000.00 |
| Apr 30, 2025 | 131,000.00 |
| Apr 30, 2025 | 131,000.00 |
| Jan 31, 2025 | 256,000.00 |
| Jan 31, 2025 | 256,000.00 |
| Oct 31, 2024 | 9,000.00 |
| Oct 31, 2024 | 9,000.00 |
| Jul 31, 2024 | 258,000.00 |
| Jul 31, 2024 | 258,000.00 |
| Apr 30, 2024 | 263,000.00 |
| Apr 30, 2024 | 263,000.00 |
| Jan 31, 2024 | 379,000.00 |
| Jan 31, 2024 | 379,000.00 |
| Oct 31, 2023 | 53,000.00 |
| Oct 31, 2023 | 53,000.00 |